Live Breaking News & Updates on Hazard ratio

Stay informed with the latest breaking news from Hazard ratio on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Hazard ratio and stay connected to the pulse of your community

CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

Recommendation based on results from CheckMate -901, the first Phase 3 trial with an immunotherapy-chemotherapy combination to demonstrate a survival benefit versus standard-of-care chemotherapy...

United-states , Japan , Taiwan , South-korea , China , Bristol-myers-squibb , Dana-walker , European-medicines-agency , Company-opdivo , Twitter , Instagram , Global-program

SGLT2 Inhibitors Reduce Risk of New Gout Diagnoses in T2D Relative to Sulfonylurea

A propensity score-matched, new-user analysis suggests SGLT2 inhibitors may reduce gout risk in type 2 diabetes patients relative to other second-line therapies.

Canada , United-kingdom , Massachusetts , United-states , Canadian , British , Natalie-mccormick , American-college-of-rheumatology-natalie-mccormick , Harvard-medical-school , American-college , British-columbia , Massachusetts-general-hospital

SMART-C Meta-Analysis: SGLT2 Inhibitors Reduce Cardiovascular Events

Meta-analysis of 11 phase 3 trials shows SGLT2 inhibitors reduce cardiovascular event risk by 9% across diverse patient populations.

George-institute-for-global-health , Renal-trialist-consortium , Brendon-neuen , Research-fellow , George-institute , Analysis-cardio-renal-trialist-consortium , Hazard-ratio , Confidence-interval , Glucose-co-transporter , Major-adverse-cardiovascular-outcomes , Redefining-cardiometabolic

REDUCE-IT Analysis Outlines Benefit of Icosapent Ethyl Across Range of LDL-C Levels

A new analysis of the REDUCE-IT trial reveals the benefits of icosapent ethyl in reducing cardiovascular outcomes regardless of LDL-C levels.

Linkedin-rahul-aggarwal , Rahul-aggarwal , Office-of-the-commissioner , Harvard-medical-school , Drug-administration , American-college-of-cardiology , American-college , Annual-scientific-session , Hazard-ratio , Confidence-interval , Annual-scientific

Ankeet Bhatt, MD, MBA: NUDGE-FLU Analysis in Patients With and Without Myocardial Infarction

Ankeet Bhatt, MD, MBA, discusses a NUDGE-FLU analysis from ACC.24 examining effect of the CV gain-framed nudge in patients with and without history of AMI.

San-francisco , California , United-states , Denmark , Danish , Physician-at-kaiser-san-francisco-medical-center , American-college-of-cardiology , Anklet-bhatt , American-college , Annual-scientific-session , Kaiser-permanente-northern-california

Safia Chatur, MD: Sacubitril/Valsartan Offers Benefit in HFrEF Across New KDIGO Risk Classes

Safia Chatur, MD, discusses the results of a PARADIGM-HF analysis at ACC.24 examining the effects of ARNI use across the updated 2024 KDIGO Risk Classifications.

Massachusetts , United-states , Safia-chatur , Coll-cardiol , Work-group , American-college-of-cardiology , American-college , Annual-scientific-sessions , Disease-improving-global-outcomes , Massachusetts-general-hospital , Hazard-ratio , Confidence-interval

ACC.24 Clinical Trials Recap, with Deepak Bhatt, MD, MPH, MBA

Deepak Bhatt, MD, MPH, MBA, provides a recap of top trials and new data from the American College of Cardiology's 2024 Annual Scientific Session.

United-states , American , Eli-lilly , Deepak-bhatt , Astrazeneca , Journal-of-the-american-medical-association , American-college-of-cardiology , Amgen , Pfizer , American-college , Annual-scientific-session , New-england-journal

SGLT2 Inhibition Across a Range of Left Ventricular Hypertrophy, with Muthiah Vaduganathan, MD, MPH

Muthiah Vaduganathan, MD, MPH, discusses a presentation from ACC.24 assessing the effects of dapagliflozin across a range of left ventricular hypertrophy from DELIVER.

Campbellp-dapagliflozin , Muthiah-vaduganathan , Boehringer-ingelheim-pharmaceuticals , Astrazeneca , Bayer-ag , Amgen , American-college-of-cardiology , American-college , Annual-scientific-sessions , Cardiometabolic-implementation-science , Hazard-ratio , Confidence-interval

AEGIS-II Misses Primary Endpoint, Suggests Potential for CSL112 in Hyperlipidemia

CSL112 infusion did not reduce major cardiovascular events at 90 days but further analysis suggests patients with elevated LDL-C levels could derive significant benefit.

Weill-cornell , C-michael-gibson , Robert-harrington , Gibson , Institute-for-clinical-research , American-college-of-cardiologyc-michael-gibson , Harvard-medical-school , American-college-of-cardiology , Provost-for-medical-affairs-of-cornell-university , American-college , Annual-scientific , Hazard-ratio

European Commission Expands Approval of Bristol Myers Squibb's Reblozyl (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)

European Commission Expands Approval of Bristol Myers Squibb's Reblozyl (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United-kingdom , United-states , Milan , Lombardia , Italy , Japan , Scotland , American , Britain , Dennis-riedl , Bristol-myers-squibb , Monica-shaw